MedTrace Logo

Selective, Micropulse and Pattern Laser Trabeculoplasty in Medically Treated Open-angle Glaucoma.

NCT07756411 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-08-10

No results posted yet for this study

Summary

This randomized, single-centre, three-arm trial compared three subvisible laser trabeculoplasty delivery protocols in eyes with open-angle glaucoma already receiving intraocular pressure (IOP)-lowering medication: selective laser trabeculoplasty (SLT, 3-nanosecond pulses), micropulse laser trabeculoplasty (MLT, 577 nm with 15% duty cycle), and pattern laser trabeculoplasty (PLT, 5-ms pattern delivery). Ninety eyes of 90 patients were allocated 1:1:1 to a single 360-degree session and followed for 6 months. The primary outcome was IOP at 6 months, with an equivalence margin of +/-2.0 mmHg prespecified for pairwise comparisons. Secondary outcomes were percentage IOP change, number of IOP-lowering medications, cumulative treatment success (IOP reduction of at least 20% from baseline without an increase in medications), and adverse events. Outcome assessment was performed by a second ophthalmologist masked to allocation and to clinical history.

Conditions

Interventions

DEVICE

Selective laser trabeculoplasty

Nanosecond-pulse laser trabeculoplasty delivered over 360 degrees with a Tango laser (Ellex Medical Lasers, Adelaide, Australia) after two drops of pilocarpine 2% and topical anaesthetic.

DEVICE

Micropulse laser trabeculoplasty

Micropulsed 577-nm laser trabeculoplasty delivered over 360 degrees with an IQ 577 laser (Iridex, Mountain View, California, USA) after two drops of pilocarpine 2% and topical anaesthetic.

DEVICE

Pattern laser trabeculoplasty

Short-exposure pattern laser trabeculoplasty delivered over 360 degrees with a Pascal Streamline 577 (Topcon, Tokyo, Japan) after two drops of pilocarpine 2% and topical anaesthetic.

Sponsors & Collaborators

  • University of Udine

    lead OTHER

Principal Investigators

  • Daniele Veritti · Department of Ophthalmology, University of Udine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2026-04-01
Completion
2026-05-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07756411 on ClinicalTrials.gov